Oxigene inc,wie Kerxy vor 2 jahren:Einstiegskurse!
Seite 1 von 2 Neuester Beitrag: 12.05.11 23:32 | ||||
Eröffnet am: | 17.07.10 16:13 | von: Chalifmann3 | Anzahl Beiträge: | 36 |
Neuester Beitrag: | 12.05.11 23:32 | von: Oettinger | Leser gesamt: | 5.523 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < | 2 > |
OXiGENE Announces Clinical Data From FACT Study to be Presented at the 14th International Thyroid Congress
SOUTH SAN FRANCISCO, Calif., June 24, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC), will be presented at the upcoming 14th International Thyroid Congress in Paris, France, on September 12, 2010. OXiGENE will release a summary of results immediately after they are presented
Oral Presentation Title: RANDOMIZED PHASE 2/3 TRIAL OF A TUMOR VASCULAR DISRUPTING AGENT FOSBRETABULIN TROMETHAMINE (CA4P) WITH CARBOPLATIN (C), AND PACLITAXEL (P) IN ANAPLASTIC THYROID CANCER (ATC): INTERIM SAFETY AND EFFICACY RESULTS OF THE FACT TRIAL
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.
MFG
Chali
Wie siehst Du die Entwicklung in den nächsten 2 Jahren.
Vielen Dank.
Haben noch ca. 14 Millionen USD an Cash, wobei der Verlust im ersten Quartal 2010 bei ca. 11 Millionen USD lag...
Aber als Termin halte ich mir erst mal den 12.Sept warm,wenn Oxigene ihre Phase 2/3 Daten in Paris veröffentlicht,die sollen nämlich sehr gut sein !
Bis dahin !
MFG
Chali
Werden im Moment einiges an Aktien auf dem Markt geschmiesen.
Gruß.
MFG
Chali
ich da was falsch gelesen oder verstanden ?
Glaub das bloss nicht !!
MFG
Chali
Schau mal nach. Dort steht es.
MFG
Chali
http://secfilings.nasdaq.com/...=10-Q&RcvdDate=4/29/2010&pdf=
Schaut Euch mal AVII an. Die haben am Freitag einen Kontrakt mit einer Behörde des U.S.-Verteigigungsministeriums geschlossen, der ihnen 291 Millionen USD bringt. Derzeit wird die Gesellschaft mit gerademal knapp 200 Millionen USD bewertet.
Denke hier lauert noch erhebliches Potential...
dann sage mir Bitte wieviel Cash Sunesis zum 30.06.2010 hat.
Wer Du mehr weist, dann bitte verlinken!
MFG
Chali
http://www.thestreet.com/_nasdaq/story/10812353/1/...EE&cm_ite=NA
MFG
Chali
SOUTH SAN FRANCISCO, Calif., June 24, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC), will be presented at the upcoming 14th International Thyroid Congress in Paris, France, on September 12, 2010. OXiGENE will release a summary of results immediately after they are presented.
ZYBRESTAT Presentation Details:
Oral Presentation Title: RANDOMIZED PHASE 2/3 TRIAL OF A TUMOR VASCULAR DISRUPTING AGENT FOSBRETABULIN TROMETHAMINE (CA4P) WITH CARBOPLATIN (C), AND PACLITAXEL (P) IN ANAPLASTIC THYROID CANCER (ATC): INTERIM SAFETY AND EFFICACY RESULTS OF THE FACT TRIAL
Presenter: Rossella Elisei, M.D.
Session Title: Prospective trials in refractory thyroid cancers
Date: Sunday 12 Sept.
Time of session: 14:45 - 16:15
Location: Room Bordeaux - level 3
About ZYBRESTAT (fosbretabulin)
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
MFG
Chali
Als Treadgründer hast Du doch das Papierchen immer über den grünen Klee hinaus gelobt.
Woher der Sinneswandel?
Gruß Wilbär.
PS.Allein aus diesem Grunde bin ich auch dabei.
Was hältst Du als Biospezi eigentlich von YM-Bio?
Gruß Wilbär.